Search research articles
Contact Us
Filters
Showing results (241-250 of 275) with videos related to
Page
of 28
Sort By:
JCO Oncology Practice
|
August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality
Joseph M Unger, Hillary Stires, Laura A Levit, et al.
Journal of Immunotherapy and Precision Oncology
|
May 9, 2024
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR)
Abdul-Rahman Jazieh, Adda Bounedjar, Hikmat Abdel-Razeq, et al.
Science Translational Medicine
|
March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligo
Jeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Haematologica
|
June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Judith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
The Journal of Urology
|
April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
Adam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
July 15, 2026
Palbociclib in Patients With Ovarian Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Dan S Veljovich, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 275) with videos related to
Sort By:
Page
of 28
JCO Oncology Practice
|
August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality
Joseph M Unger, Hillary Stires, Laura A Levit, et al.
Journal of Immunotherapy and Precision Oncology
|
May 9, 2024
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR)
Abdul-Rahman Jazieh, Adda Bounedjar, Hikmat Abdel-Razeq, et al.
Science Translational Medicine
|
March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligo
Jeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Haematologica
|
June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Judith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
The Journal of Urology
|
April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
Adam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
JCO Precision Oncology
|
April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
July 15, 2026
Palbociclib in Patients With Ovarian Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Dan S Veljovich, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Page
of 28